Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Head & Neck 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 9Carcinoma, Neuroendocrine 2Carcinoid Tumor 2Thyroid Carcinoma, Anaplastic 1Small Cell Lung Carcinoma 1Pheochromocytoma 1Paraganglioma 1Non functioning pancreatic endocrine tumor 1Metastatic Digestive System Neuroendocrine Tumor G1 1Gastro-enteropancreatic neuroendocrine tumor 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Adenoma, Islet Cell 1Adenocarcinoma 1

Interventions

zimberelimab 1tislelizumab 1surufatinib 1cabozantinib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × cabozantinib × NET × Clear all
NCT04400474 2025-06-19

CABATEN

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
93 enrolled 17 charts
CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡